Law360, New York (May 10, 2011, 10:11 PM ET) -- The Federal Trade Commission said on Tuesday that Sanofi-Aventis U.S. LLC and two generic-drug makers violated federal law by failing to report patent infringement pacts that resolved suits over Sanofi’s Ambien CR, but the companies were let off with a warning.
The FTC’s Bureau of Competition sent advisory letters to Sanofi, Watson Pharmaceuticals Inc., and Synthon Holding BV on Monday notifying the companies that the regulatory agency had recommended no enforcement action.
The FTC revealed that the settlements in question had not harmed consumers or competition,...
Sanofi, Generics Failed To Report Ambien IP Deals: FTC
To view the full article, take a free trial now.
